Although Nrf2 activation has been postulated as a possible therapeutic target to treat diseases associated with intravascular hemolysis (Keleku-Lukwete et al., 2015; Doss et al., 2016; Ghosh et al., 2016; Vasconcellos et al., 2016; Belcher et al., 2017), additional studies are needed to unravel the specific effect of Nrf2 activation in kidney in this pathological setting. The gene discussed is NFE2L2; the disease is hemolysis.